The antiserum was produced against synthesized peptide derived from human HIRA around the phosphorylation site of Thr555. AA range:521-570

Phospho-HIRA (T555) Polyclonal Antibody detects endogenous levels of HIRA protein only when phosphorylated at T555.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):LTtPS

HIRA

Protein HIRA

HIRA ;
DGCR1 ;
HIR ;
TUPLE1 ;
Protein HIRA ;
TUP1-like enhancer of split protein 1

This gene encodes a histone chaperone that preferentially places the variant histone H3.3 in nucleosomes. Orthologs of this gene in yeast, flies, and plants are necessary for the formation of transcriptionally silent heterochomatin. This gene plays an important role in the formation of the senescence-associated heterochromatin foci. These foci likely mediate the irreversible cell cycle changes that occur in senescent cells. It is considered the primary candidate gene in some haploinsufficiency syndromes such as DiGeorge syndrome, and insufficient production of the gene may disrupt normal embryonic development. [provided by RefSeq, Jul 2008],

developmental stage:Expressed during embryogenesis.,Disease:May play a part in the etiology of the DiGeorge syndrome (DGS), a developmental disorder due to an abnormal development of the third and fourth pharyngeal pouches. The clinical features include absence or hypoplasia of the thymus and parathyroid glands, cardiovascular malformations, facial dysplasia, a cleft palate and mental retardation.,Function:Cooperates with ASF1A to promote replication-independent chromatin assembly. Required for the periodic repression of histone gene transcription during the cell cycle. Required for the formation of senescence-associated heterochromatin foci (SAHF) and efficient senescence-associated cell cycle exit.,PTM:Phosphorylated by CDK2/CCNA1 and CDK2/CCNE1 on Thr-555 in vitro. Also phosphorylated on Thr-555 and Ser-687 in vivo.,PTM:Sumoylated.,similarity:Belongs to the WD repeat HIR1 family.,similarity:Contains 8 WD repeats.,subcellular location:Primarily, though not exclusively, localized to the nucleus. Localizes to PML bodies immediately prior to onset of senescence.,subunit:Interacts with histone H3F3B, PAX3 and PAX7 (By similarity). Interacts with CCNA1, HIRIP3, NFU1/HIRIP5 and histone H2B. Part of a complex which includes ASF1A, CABIN1, histone H3.3, histone H4 and UBN1.,tissue specificity:Expressed at high levels in kidney, pancreas and skeletal muscle and at lower levels in brain, heart, liver, lung, and placenta.,

Nucleus. Nucleus, PML body. Primarily, though not exclusively, localized to the nucleus. Localizes to PML bodies immediately prior to onset of senescence.

Expressed at high levels in kidney, pancreas and skeletal muscle and at lower levels in brain, heart, liver, lung, and placenta.